Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | CDC42 | P60953 | 1/20 | 0.36 |
| ▸ | RAC1 | P63000 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961040 | 0.90 | OPRD1 (0.38) | POLBSLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL3951822 | 0.85 | ALDH1A1 (0.39) | LMNA | |
| SCHEMBL3960216 | 0.85 | SLC6A2 (0.35) | POLBSLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL3955382 | 0.85 | SLC6A2 (0.35) | POLBSLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL4510820 | 0.85 | ALDH1A1 (0.40) | SLC6A2SLC6A4SLC6A3LMNA | |
| SCHEMBL3957323 | 0.84 | SLC6A3 (0.38) | SLC6A2SLC6A4SLC6A3CNR1 | |
| SCHEMBL4499897 | 0.84 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3GPR119 | |
| SCHEMBL4508910 | 0.82 | LMNA (0.38) | SLC6A2SLC6A4LMNAPTGS1 | |
| SCHEMBL3961104 | 0.82 | PDK2 (0.32) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL3985546 | 0.82 | POLB (0.50) | POLBSMYD3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7524846-B2 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2009-04-28 | — | — | US | disclosed |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | POLB 1897/4885SMYD3 1273/4885SLC6A2 108/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | POLB 1768/4885SMYD3 1021/4885SLC6A2 71/4885 |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | COMT, MAOA, HTR3A | POLB 2479/4885SMYD3 2494/4885SLC6A2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.